NEUROTECH INTERNATIONAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.073 AUD | -1.35% |
|
-6.41% | +5.80% |
| 04-17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
| 04-17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 50.12M | - | - | - | - | - | |
| 63.85B | - | |||||
| 41.83B | ||||||
| 40.47B | ||||||
| 27.17B | ||||||
| 26.52B |
